We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of ex vivo-expanded γδ-T cells combined with galectin-1 antibody on the growth of human cervical cancer xenografts in SCID mice.
- Authors
Hua Li; Yubin Wang; FuXiang Zhou
- Abstract
Objective: To investigate the antitumor activity of ex vivoexpanded -T cells derived from tumor-infiltrating lymphocytes( TILs) from cervical cancer patients when combined with galectin-1 antibody and studied both in vitro and in vivo. Methods: The presence of TILs in cervical cancer specimens was detected by immunohistochemistry and TILs were expanded using the solid-phase antibody method. The expression of galectin-1 by the human cervical cancer cell line, SiHa, was measured by Western blot and ELISA. In vitro cytotoxic activities of expanded TILs, with or without galectin-1 inhibitor, were determined using the LDH-release test. In vivo antitumor activity of TILs, combined with galectin-1 antibody, was evaluated using the SCID mouse model. Results: TILs existed in the cervical cancer and the percentage of TCR+ cells in TILs after ex vivo expansion was 91.2±1.2% detected by flow cytometry. SiHa cell expressed and secreted galectin-1 as measured by Western blot and ELISA. Expanded TILs from human cervical cancer demonstrated marked cytotoxicity to SiHa or Hela cells. In comparison with non-treated group, the cytotoxicity of TILs towards SiHa or Hela cell was significantly increased when effector and target cells were incubated with either lactose or galectin-1 antibody at E/T ratio of 1:1 (p<0.05). TILs, in combination with galectin-1 antibody treatment, significantly suppressed the growth of xenografts in SCID mice, in comparison with all other groups (p<0.05). TILs alone also showed the ability to inhibit tumour growth in vivo, but were more efficient when combined with specific antibody (p<0.05). Conclusion: Taken together, our results suggest that -T cells, combined with galectin-1 antibody treatment, could be a more effective adoptive immunotherapy for patients with cervical cancer than traditional adoptive immunotherapy methods.
- Subjects
LYMPHOCYTES; CERVICAL cancer patients; IMMUNOHISTOCHEMISTRY; FLOW cytometry; IMMUNOTHERAPY
- Publication
Clinical & Investigative Medicine, 2010, Vol 33, Issue 5, pE280
- ISSN
0147-958X
- Publication type
Article
- DOI
10.25011/cim.v33i5.14353